Board of Pharmacy Warns of Fake Callers
The Board of Pharmacy is warning licensees to be aware of scam callers claiming to represent the California State Board of Pharmacy or another government agency. In many cases, callers are attempting to extort money or elicit sensitive information — e.g., license numbers, DEA registration numbers, etc. — from licensees.
DHCS to Begin Processing Retroactive FFS Pharmacy Claims Adjustments
On Aug. 17, the Department of Health Care Services (DHCS) and its Medi-Cal Rx contractor Magellan posted an updated provider bulletin notifying pharmacy providers of its plan to recommence pharmacy outpatient drug retroactive fee-for-service (FFS) claims adjustments with dates of service from May 2017 through February 2019.
CHA Issues Summary of Proposed Remedy for Prior 340B Payment Cuts
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of the proposed remedy issued by the Centers for Medicare & Medicaid Services (CMS) for its 340B-acquired drug payment policy that was in effect from 2018-2022 for hospitals paid under the outpatient prospective payment system. The proposal is in response to a remand from the U.S. District Court for the District of Columbia and the U.S. Supreme Court’s decision in American Hospital Association v. Becerra.
CMS Proposes 340B Repayment Policy for 2018-2022
As a result of the Supreme Court ruling in American Hospital Association v. Becerra, the Centers for Medicare & Medicaid Services (CMS) issued its proposed remedy for its 340B-acquired drug payment policy that was in effect from 2018-2022. The rule proposes to make a hospital-specific lump sum settlement of an estimated $9 billion to approximately 1,600 340B-eligible hospitals paid under the outpatient prospective payment system (OPPS).
CHA Comments on Proposed Changes to 340B ADR Process
CHA has submitted comments on the proposed rule updating the 340B administrative dispute resolution (ADR) process. In the letter, CHA generally supported the proposed rule from the Health Resources and Services Administration. CHA offered specific comments on the revised ADR panel role, structure, and the elimination of the minimum threshold of the disputed claims.
FDA Offers Guidance to Help Increase Supply of Certain Ibuprofen Products
The Food and Drug Administration (FDA) has issued guidance, effective immediately, on compounding certain ibuprofen oral suspension products in the wake of record high demand for the product.
340B Case Remanded to HHS to Determine Underpayment Remedy
On Jan. 10, the U. S. District Court for the District of Columbia sent a case about 340B underpayments back to the Department of Health and Human Services (HHS).
CHA Issues Summary of Proposed Changes to 340B Administrative Dispute Resolution Process
CHA has issued a detailed summary of the proposed rule updating the 340B administrative dispute resolution (ADR) process.
HRSA Issues Long-Awaited Proposed Rule on Administrative Dispute Resolution Process
The Health Resources and Services Administration has issued a long-awaited proposed rule updating the 340B administrative dispute resolution (ADR) process.
FDA Issues Guidance for Compounding of Amoxicillin to Alleviate Shortages
Due to increased demand, the U.S. Food and Drug Administration (FDA) has added amoxicillin oral powder for suspension to the drug shortage list and has issued guidance — in effect immediately — on its compounding.